

IT'S TIME TO LEVEL THE **PLAYING FIELD**

Certain brand pharmaceutical companies are blocking competition while increasing prices for life-saving medicine. The bipartisan CREATES Act (S. 340/ H.R. 965) would level the playing field and save patients billions in lower drug costs.






IMAGINE AAM AS YOUR QB.


WE LEAD THE TEAM, WORKING HARD TO BRING SAFE, EFFECTIVE, AND AFFORDABLE GENERICS AND BIOSIMILARS TO MARKET.

BIG PHARMA IS A FORMIDABLE FOE.

Every play we run, brand companies stand in the way and bend the rules of the game to win.



CERTAIN BRAND PHARMACEUTICAL COMPANIES LIMIT ACCESS TO SAMPLES AT EVERY TURN BY RESTRICTING DISTRIBUTION EVEN WHEN THE FDA TELLS THEM IT'S SAFE TO SELL THEIR PRODUCT TO POTENTIAL COMPETITORS.







NEGOTIATIONS OVER SHARED REMS ARE OFTEN DELAYED OR AVOIDED ALTOGETHER BY CERTAIN BRAND PHARMACEUTICAL COMPANIES TO THWART COMPETITION.

THE REFEREES ARE SIDELINED

CONGRESS NEEDS TO PROVIDE BETTER TOOLS TO THE FDA AND THE COURTS TO ENSURE MORE GENERICS AND BIOSIMILARS CAN COME TO MARKET.



IN THE RED (ZONE)

\$5,400,000,000

PATIENTS WOULD SAVE \$5.4 BILLION ANNUALLY IN LOWER DRUG COSTS IF THE CREATES ACT WERE SIGNED INTO LAW.



LET'S SCORE **GREATER** SAVINGS. WITH THE CREATES ACT, GENERICS AND

BIOSIMILARS MANUFACTURERS ARE ABLE TO SCORE GREATER SAVINGS FOR PATIENTS AND TAXPAYERS.

LOSE AND ONLY BIG PHARMA WINS.

WHEN THE GAME IS RIGGED, PATIENTS





IT'S TIME TO TACKLE HIGH DRUG PRICES! **SUPPORT PASSAGE OF THE CREATES ACT!**

Learn more at: stopREMSabuse and use #stopREMSabuse

The Association for Accessible Medicines promotes policies, including greater competition, to ensure more generic and biosimilar medicines are more accessible to more people who need them. Learn more at accessiblemeds.org.